What is true about CBD in relation to CB1 and CB2 receptors?

Cannabidiol (CBD) is a compound found in cannabis that interacts with the endocannabinoid system, but it does so in a unique way compared to other cannabinoids like THC. The relationship of CBD to CB1 and CB2 receptors is critical in understanding its pharmacological effects.

CBD does not act as a full agonist at either CB1 or CB2 receptors. Instead, it has been shown to have a more complex interaction with these receptors. While it can bind to them, it does not activate them in the same way that other cannabinoid agonists, such as THC, do. Instead, CBD often acts as a negative or inverse agonist at CB1 and less prominently at CB2, meaning it can inhibit the action of other cannabinoids that act as agonists.

The assertion that CBD does not bind to CB1 or CB2 is misleading. While it does bind to these receptors, it does so in a manner that does not produce the characteristic effects associated with full agonism. Instead, it may influence the endocannabinoid system through other mechanisms, including modulating receptor activity or interacting with non-cannabinoid receptors.

In the context of its interaction with the endocannabinoid system, CBD's role is more nuanced, as it may provide